게인 테라퓨틱스(GANX)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $1.79 (+0.56%), 시가총액 $0.08B, 52주 최저~최고 $1.44 ~ $4.18.
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. The company's drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. Its lead drug candidate is GT-02287, which is currently in a Phase 1b study for the treatment of Parkinson's disease with or without a GBA1 mutation. The company has various small molecule drug candidates, which are in the discovery, research, and preclinica
게인 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
게인 테라퓨틱스의 현재 주가는 $1.79 (+0.56%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
게인 테라퓨틱스의 시가총액은 약 $0.08B입니다.
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia.